Silence Therapeutics granted two US patents

Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.

Shares in biotechnology firm Silence Therapeutics took a hit on Monday despite the company revealing that the US Patent and Trademark Office (USPTO) has granted its two new patents.

The patents, which are for both its interfering RNA molecules and lipid complexes used in drug delivery, will extend Silence's intellectual property in these areas of research.

Subscribe to MoneyWeek

Become a smarter, better informed investor with MoneyWeek.

Dr. Klaus Giese, Chief Scientific Officer of Silence, said: "These notifications from the USPTO further strengthens Silence's IP position in the arena of RNA interference (RNAi) therapeutics and builds upon the already strong proprietary technology Silence offers its partners. The broad range of RNAi therapeutics in terms of their possible length of base pairs again distinguishes Silence from competitors which provide coverage for only very few lengths, if any.

"We welcome the decision of the USPTO on drug delivery as an appreciation of Silence's contribution. With this patent, Silence is becoming an even more attractive partner for companies interested in the delivery of a variety of classes of compounds with siRNA and miRNA being only two of them."

Advertisement
Advertisement - Article continues below
Advertisement

Recommended

Visit/investments/investment-strategy/600861/how-demographics-affects-stock-valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Visit/investments/stocks-and-shares/600863/sirius-minerals-anglo-american-takeover
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Visit/investments/stockmarkets/600634/why-investors-should-be-cautiously-bullish-for-2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020
Visit/investments/stocks-and-shares/share-tips/600636/class-acts-going-cheap-buy-into-europes-best
Share tips

Class acts going cheap: buy into Europe’s best bargains

Value investing appears to be making a comeback, while shares on this side of the Atlantic are more appealing on metrics such as price/earnings ratios…
16 Jan 2020

Most Popular

Visit/investments/600992/the-helicopters-are-being-warmed-up-we-might-be-closer-to-a-bottom-than-you
Investments

The helicopters are being warmed up – we might be closer to a bottom than you think

Governments are starting to act to bolster their economies against coronavirus. But, asks John Stepek, will throwing money at the problem slow the mar…
17 Mar 2020
Visit/investments/commodities/gold/600998/extraordinary-times-buy-gold-buy-silver
Gold

Extraordinary times create extraordinary opportunities – these assets look cheap

With the stage set for some monumental fiscal stimulus, this is most definitely a time to own some gold. And if you’re bold enough, says Dominic Frisb…
18 Mar 2020
Visit/investments/funds/investment-trusts/600975/now-could-be-a-good-time-to-bag-an-investment-bargain
Investment trusts

Now could be a good time to bag an investment bargain

We like investment trusts here at MoneyWeek. And they can be even better during a market crash.
16 Mar 2020
Visit/investments/commodities/600729/the-rare-earth-metal-that-wont-be-a-secret-for-long
Sponsored

The rare earth metal that won't be a secret for long

SPONSORED CONTENT – You can’t keep a good thing hidden forever; now is the time to consider Pensana Rare Earths and the rare earth metals NdPr.
31 Jan 2020